Announcing the Launch of Our Redesigned Newsletter

Dear All,

It is said that change is the only constant in life. That's certainly true for our editors here, who have worked tirelessly to develop the new aesthetic, simplified and easy accessible design of Lambda Clinical Research Newsletter.

With the October issue, I am pleased to announce the redesign of our newsletter; it will be published as an e-Newsletter, the first issue of which we are releasing this month. The newsletter will contain information of interest to our users categorized into different sections including Global News, Pharma India, Regulatory Round-Up, Drugs Approvals and Launches, Drugs in Development and Clinical Trials, Merger/ Acquisition/ Collaborations and Patents and Technology related news.

We have tried to include more information that may help you gain more knowledge regarding the news items which is the major change in content from our previous newsletter.

Our goal with this newsletter is to create something that is candid, genuine and beneficial to our customers in their fast lives and which will eventually facilitate as a channel between us and our growing customer community.

I appreciate you taking the time to read the newsletter and look forward for your views. Your feedback is very important to us as we strive to develop a newsletter that is valuable to you.

If you are interested in contributing, please let us know

Dr. Tausif Monif

President - Global operations

Contact Us

  • Dr. Tausif Monif
    President - Global operations
  • Dr. Mrinal Kammili
    Ex. Director – Global Head, BD

Disclaimer: “The information compiled and published in this newsletter have been collected from various public domain resources available on web and relevant magazines. The Public Domain information is not confidential and may be freely distributed and copied. However, transmission or reproduction of protected items beyond that allowed by fair use as defined in the copyright laws requires the written permission of the copyright owners, if any. Lambda directly or indirectly shall not be responsible for any legal/ethical litigation claimed by any professional agency / bodies.”


From the editor's desk